Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Osteoporosis: the current status of mesenchymal stem cell-based therapy.

Phetfong J, Sanvoranart T, Nartprayut K, Nimsanor N, Seenprachawong K, Prachayasittikul V, Supokawej A.

Cell Mol Biol Lett. 2016 Aug 12;21:12. doi: 10.1186/s11658-016-0013-1. eCollection 2016. Review.

2.

A missense single nucleotide polymorphism in the ALDH2 gene, rs671, is associated with hip fracture.

Takeshima K, Nishiwaki Y, Suda Y, Niki Y, Sato Y, Kobayashi T, Miyamoto K, Uchida H, Inokuchi W, Tsuji T, Funayama A, Nakamura M, Matsumoto M, Toyama Y, Miyamoto T.

Sci Rep. 2017 Mar 27;7(1):428. doi: 10.1038/s41598-017-00503-2.

3.

Unmet needs and current and future approaches for osteoporotic patients at high risk of hip fracture.

Ferrari S, Reginster JY, Brandi ML, Kanis JA, Devogelaer JP, Kaufman JM, Féron JM, Kurth A, Rizzoli R.

Arch Osteoporos. 2016 Dec;11(1):37. Epub 2016 Oct 31. Review. Erratum in: Arch Osteoporos. 2017 Dec;12 (1):25.

4.

We need a break: Bisphosphonates.

Jaiman A, Sabat D, Arora S, Hafez MA.

J Clin Orthop Trauma. 2013 Mar;4(1):11-4. doi: 10.1016/j.jcot.2013.01.010. Epub 2013 Feb 6. Review.

5.

A model of BMD changes after alendronate discontinuation to guide postalendronate BMD monitoring.

McNabb B, Vittinghoff E, Eastell R, Schwartz AV, Bauer DC, Ensrud K, Barrett-Connor E, Black DM.

J Clin Endocrinol Metab. 2014 Nov;99(11):4094-100. doi: 10.1210/jc.2014-1193. Epub 2014 Aug 15.

6.

Alendronate sodium hydrate (oral jelly) for the treatment of osteoporosis: review of a novel, easy to swallow formulation.

Imai K.

Clin Interv Aging. 2013;8:681-8. doi: 10.2147/CIA.S37199. Epub 2013 Jun 7. Review.

7.

Evaluation of bone remodelling parameters after one year treatment with alendronate in postmenopausal women with osteoporosis.

Kučukalić-Selimović E, Valjevac A, Hadžović-Džuvo A, Skopljak-Beganović A, Alimanovic-Alagić R, Brković A.

Bosn J Basic Med Sci. 2011 Feb;11(1):41-5.

8.

Femoral insufficiency fractures associated with prolonged bisphosphonate therapy.

Isaacs JD, Shidiak L, Harris IA, Szomor ZL.

Clin Orthop Relat Res. 2010 Dec;468(12):3384-92. doi: 10.1007/s11999-010-1535-x. Epub 2010 Aug 31.

9.

Gallium modulates osteoclastic bone resorption in vitro without affecting osteoblasts.

Verron E, Masson M, Khoshniat S, Duplomb L, Wittrant Y, Baud'huin M, Badran Z, Bujoli B, Janvier P, Scimeca JC, Bouler JM, Guicheux J.

Br J Pharmacol. 2010 Apr;159(8):1681-92.

10.

Prevention of osteoporosis-related fractures among postmenopausal women and older men.

Rahmani P, Morin S.

CMAJ. 2009 Nov 24;181(11):815-20. doi: 10.1503/cmaj.080709. Epub 2009 Oct 19. Review. No abstract available.

11.

Comparison of the effects of alendronate and alfacalcidol on hip bone mineral density and bone turnover in Japanese men having osteoporosis or osteopenia with clinical risk factors for fractures.

Iwamoto J, Sato Y, Uzawa M, Takeda T, Matsumoto H.

Yonsei Med J. 2009 Aug 31;50(4):474-81. doi: 10.3349/ymj.2009.50.4.474. Epub 2009 Aug 19.

12.

Diagnosis and management of osteoporosis in the older senior.

Vondracek SF, Linnebur SA.

Clin Interv Aging. 2009;4:121-36. Epub 2009 May 14. Review.

13.
14.

Alendronate treatment results in similar levels of trabecular bone remodeling in the femoral neck and vertebra.

Diab T, Allen MR, Burr DB.

Osteoporos Int. 2009 Apr;20(4):647-52. doi: 10.1007/s00198-008-0717-9. Epub 2008 Aug 21.

15.
16.

Comparison of effects of alendronate and raloxifene on lumbar bone mineral density, bone turnover, and lipid metabolism in elderly women with osteoporosis.

Iwamoto J, Sato Y, Uzawa M, Takeda T, Matsumoto H.

Yonsei Med J. 2008 Feb 29;49(1):119-28. doi: 10.3349/ymj.2008.49.1.119. Retraction in: Yonsei Med J. 2018 Jan;59(1):167.

17.

Osteoporosis medication profile preference: results from the PREFER-US study.

Weiss TW, McHorney CA.

Health Expect. 2007 Sep;10(3):211-23.

18.

Supplemental Content

Support Center